Get started
Author

Jenny Mattsson

Observed names: Jenny Mattson, Mattsson, Jenny
Institution: BioInvent (Sweden)
ORCID: 0009-0001-6852-6215
Observed ORCID: 0009-0001-6852-6215
OpenAlex ID: A5081297086
Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo
2015 · Ali Roghanian, Ingrid Teige, et al. · Cancer Cell · 136
PDF
Accelerating target deconvolution for therapeutic antibody candidates using highly parallelized genome editing
2021 · Jenny Mattsson, Ludvig Ekdahl, et al. · Nature Communications · 6
PDF
Genome-wide CRISPR/Cas9 screen identifies regulators of BCMA expression on multiple myeloma cells
2024 · Ram Ajore, Jenny Mattsson, et al. · Blood Cancer Journal · 5
PDF
Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al. · Cancer Research · 3
Sequence enrichment profiles enable target-agnostic antibody generation for a broad range of antigens
2023 · Jenny Mattsson, Anne Ljungars, et al. · Cell Reports Methods · 3
Supplementary Fig 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 5 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 4 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Table 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Data from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 3 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 10 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 8 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 9 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 7 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 2 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 6 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Materials and Methods from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Data from A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al.
Supplementary Figure S3 from A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al.
PDF
Supplementary Figure S1 from A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al.
PDF
Supplementary Figure S2 from A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al.
PDF
Supplementary Table 5 from A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al.
PDF
Supplementary Table 3 from A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al.
PDF
Supplementary Table 1 from A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al.
PDF
Works count: 28
Citation count: 153
H-index: 3
I10-index: 1
Year
Topic
Type